Clovis Oncology Receives Breakthrough Therapy Designation for Rucaparib for Monotherapy Treatment of Advanced Ovarian Cancer in Patients with BRCA-mutated Tumors (Inclusive of both Germline and Somatic BRCA Mutations)
April 6, 2015FDA grants Breakthrough Therapy designation for Clovis Oncology's investigational agent rucaparib to treat advanced ovarian cancer. Designation was based on results from two ongoing Phase 2 studies of rucaparib in ovarian cancer.
More »
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma
March 31, 2015Syndax and Merck form clinical trial collaboration to evaluate the combination of Syndax’s entinostat, an investigational epigenetic therapy, and Merck’s KEYTRUDA®, the first anti-PD-1 therapy approved in the U.S., to treat non-small cell lung cancer or m
More »
aTyr Pharma Secures $76 Million in Series E Financing
March 31, 2015aTyr Pharma completes a $76 million Series E financing led by new investors Sofinnova Ventures along with current investors including Domain Associates. The proceeds will towards advancing its lead program through clinical trials.
More »